Rethinking Clinical Trials

MAY 5, 2023

Assistant Professor of Medicine and Biomedical Informatics Medical Director, VICTR Center for Learning Healthcare Vanderbilt University Medical Center Slides Keywords Pragmatic Clinical Trials, Cluster-crossover Trial Key Points More than 3 million adults receive invasive mechanical ventilation each year in the U.S.

Trials 130

Trials Clinical Trials Clinical Trials Development 130

Rethinking Clinical Trials

FEBRUARY 13, 2023

The primary outcome was ventilator-free days (VFD) from start of cardiopulmonary bypass to day 28, with a number of secondary outcomes. The hypothesis was that patients with nitric oxide would recover quicker allowing for more ventilator-free days, but there was no difference between the intervention and standard of care.

Trials 130

Trials Clinical Trials Clinical Trials Research 130

Rethinking Clinical Trials

FEBRUARY 2, 2023

There was an interesting consistent pattern of subgroups of patients who were exposed earlier or more intensive positive pressure ventilation modalities, such as non-invasive ventilation, that was applied earlier in the procedure seemed to have better outcomes. It was conducted with waiver of informed consent.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

Rethinking Clinical Trials

NOVEMBER 21, 2022

Sick children, when they are acutely ill, start with standard oxygen therapy, which escalates to noninvasive respiratory support (CPAP/BIPAP or high flow nasal cannula) before invasive ventilation support in the ICU. Many other trials in the country were behind and everyone else had to stop. pctGR, @Collaboratory1.

Trials 130

Trials Clinical Trials Clinical Trials Packaging 130

World of DTC Marketing

SEPTEMBER 9, 2021

A study put a price tag on American’s bad eating habits: $50 billion a year in health care costs, attributable to cardiometabolic diseases such as heart disease, stroke, and type 2 diabetes. However, experiences among individual hospitals vary, and about one-quarter of both for-profit and not-for-profit hospitals lost money in 2016.

Drugs 222

Drugs Pharmacy Clinical Trials Clinical Trials 222

The Pharma Data

NOVEMBER 29, 2021

1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). WHO’s TAG-VE will continue to monitor and evaluate the data as it becomes available and assess how mutations in Omicron alter the behaviour of the virus. Recommended actions for countries.

Vaccination 52

Vaccination Vaccine Genome Genomics 52

XTalks

NOVEMBER 27, 2021

The technical advisory group on SARS-CoV-2 virus evolution (TAG-VE) met on Friday to discuss B.1.1.529, The World Health Organization (WHO) has declared the new variant of SARS-CoV-2 found in South Africa, first referred to as B.1.1.529, 1.1.529, to be a variant of concern (VOC) and has named it after the Greek letter Omicron (O).

Vaccination 97

Vaccination Vaccine Protein Scientist 97